HC Wainwright Reiterates “Buy” Rating for Altimmune (NASDAQ:ALT)

HC Wainwright reiterated their buy rating on shares of Altimmune (NASDAQ:ALT) in a research report report published on Monday,Benzinga reports. They currently have a $12.00 price target on the stock.

Several other equities research analysts have also recently issued reports on ALT. Stifel Nicolaus started coverage on shares of Altimmune in a research report on Wednesday, January 8th. They set a “buy” rating and a $18.00 price objective on the stock. UBS Group started coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 target price for the company. Finally, William Blair started coverage on shares of Altimmune in a research note on Friday. They issued a “market perform” rating on the stock. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Altimmune presently has a consensus rating of “Moderate Buy” and a consensus target price of $20.83.

Altimmune Stock Down 9.9 %

NASDAQ:ALT opened at $5.99 on Monday. The business’s 50-day simple moving average is $6.81 and its two-hundred day simple moving average is $7.20. Altimmune has a 52 week low of $5.28 and a 52 week high of $12.35. The stock has a market cap of $426.04 million, a PE ratio of -3.86 and a beta of 0.19.

Altimmune (NASDAQ:ALT) last released its earnings results on Thursday, February 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.34) by $0.01. Altimmune had a negative return on equity of 55.81% and a negative net margin of 199,076.92%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.00 million. Sell-side analysts anticipate that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

A number of hedge funds have recently bought and sold shares of the business. Creative Planning grew its stake in shares of Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after buying an additional 3,132 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in shares of Altimmune by 119.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 40,705 shares of the company’s stock valued at $250,000 after acquiring an additional 22,188 shares during the last quarter. Intech Investment Management LLC bought a new position in shares of Altimmune in the 3rd quarter valued at about $207,000. Charles Schwab Investment Management Inc. grew its position in Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock worth $1,299,000 after acquiring an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC bought a new stake in Altimmune during the third quarter worth approximately $31,000. Hedge funds and other institutional investors own 78.05% of the company’s stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.